Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of health insurance. A major ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...